Sector News

Novo opens ‘greenfield’ insulin plant in Russia

April 13, 2015
Life sciences
Novo Nordisk has opened a new manufacturing facility in Russia for formulation and filling of modern insulin destined for the treatment of diabetes.
 
Located at the Technopark Grabtsevo in the Kaluga region of Russia, the plant is the first and only greenfield facility for manufacturing modern insulin in the county, with environmental targets for CO² emission, water consumption and use of energy, according to the Danish drugmaker.
 
Around 10 million people in Russia are thought to have diabetes, and Novo says its move will ensure availability of high-quality modern insulins to patients. 
 
“I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia,” said Kaluga Region Governor, Anatoly Artamonov.
 
Novo currently also has production sites in Denmark, Brazil, China, France and the US.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).